Table 4.
Serological Analysis of Live Attenuated Influenza–Vaccinated Participants
| Measure and Assay | HA Subtype | Strain | Shedding Negative Samples | Shedding Positive Samples | P Valuea |
|---|---|---|---|---|---|
| Geometric mean prevaccination antibody titer (95% CI) |
|||||
| HAI | H1 | A/California/07/2009 (H1N1)pdm09 | 65.3 (48.4–88.1) | 72.9 (40–132.9) | .79 |
| H1 | A/Bolivia/559/2013 | 50.7 (38.8–66.4) | 50.4 (28.9–87.8) | .91 | |
| H3 | A/Hong Kong/4801/2014 | 187.1 (154.8–226) | 149.3 (93.4–238.6) | .31 | |
| B/Victoria | B/Brisbane/60/2008 | 88.6 (71.1–110.3) | 47.1 (28.6–77.5) | .009 | |
| B/Yamagata | B/Phuket/3073/2013 | 54.6 (43.2–69) | 45.1 (31.1–65.4) | .42 | |
| NAI | H1 | A/Bolivia/559/2013 | 152.7 (105.1–222) | 312.7 (121.6–804) | .19 |
| Seroconversion, no./No. (%) |
|||||
| HAI | H1 | A/California/07/2009 (H1N1)pdm09 | 2/96 (2) | 1/15 (7) | .36 |
| H1 | A/Bolivia/559/2013 | 5/94 (5) | 1/15 (7) | 1.00 | |
| H3 | A/Hong Kong/4801/2014 | 2/91 (2) | 0/23 (0) | 1.00 | |
| B/Victoria | B/Brisbane/60/2008 | 13/85 (15) | 6/28 (21) | .56 | |
| B/Yamagata | B/Phuket/3073/2013 | 9/86 (10) | 7/28 (25) | .07 | |
| NAI | H1 | A/Bolivia/559/2013 | 4/98 (4) | 0/15 (0) | 1.00 |
Abbreviations: CI, confidence interval; HAI, hemagglutination inhibition; NAI, neuraminidase inhibition.
aSignificant results (P < .05) are in bold.